Cargando…
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714294/ https://www.ncbi.nlm.nih.gov/pubmed/35077960 http://dx.doi.org/10.1016/j.ejca.2021.12.025 |
| _version_ | 1784623884345016320 |
|---|---|
| author | Debie, Yana Vandamme, Timon Goossens, Maria E. van Dam, Peter A. Peeters, Marc |
| author_facet | Debie, Yana Vandamme, Timon Goossens, Maria E. van Dam, Peter A. Peeters, Marc |
| author_sort | Debie, Yana |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8714294 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87142942021-12-29 Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer Debie, Yana Vandamme, Timon Goossens, Maria E. van Dam, Peter A. Peeters, Marc Eur J Cancer Letter to the Editor Elsevier Ltd. 2022-03 2021-12-29 /pmc/articles/PMC8714294/ /pubmed/35077960 http://dx.doi.org/10.1016/j.ejca.2021.12.025 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Debie, Yana Vandamme, Timon Goossens, Maria E. van Dam, Peter A. Peeters, Marc Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer |
| title | Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer |
| title_full | Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer |
| title_fullStr | Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer |
| title_full_unstemmed | Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer |
| title_short | Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer |
| title_sort | antibody titres before and after a third dose of the sars-cov-2 bnt162b2 vaccine in patients with cancer |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714294/ https://www.ncbi.nlm.nih.gov/pubmed/35077960 http://dx.doi.org/10.1016/j.ejca.2021.12.025 |
| work_keys_str_mv | AT debieyana antibodytitresbeforeandafterathirddoseofthesarscov2bnt162b2vaccineinpatientswithcancer AT vandammetimon antibodytitresbeforeandafterathirddoseofthesarscov2bnt162b2vaccineinpatientswithcancer AT goossensmariae antibodytitresbeforeandafterathirddoseofthesarscov2bnt162b2vaccineinpatientswithcancer AT vandampetera antibodytitresbeforeandafterathirddoseofthesarscov2bnt162b2vaccineinpatientswithcancer AT peetersmarc antibodytitresbeforeandafterathirddoseofthesarscov2bnt162b2vaccineinpatientswithcancer |